M&T Bank Corp Buys Shares of 8,106 Lantheus Holdings, Inc. $LNTH

M&T Bank Corp bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,106 shares of the medical equipment provider’s stock, valued at approximately $539,000.

Other large investors have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Lantheus in the third quarter valued at approximately $1,847,000. American Assets Inc. bought a new stake in Lantheus in the third quarter valued at approximately $872,000. Campbell & CO Investment Adviser LLC bought a new stake in Lantheus in the third quarter valued at approximately $2,184,000. Assetmark Inc. increased its holdings in shares of Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock worth $6,078,000 after acquiring an additional 19,844 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after acquiring an additional 115,338 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $96.23 on Wednesday. The firm has a 50-day moving average of $80.84 and a 200-day moving average of $69.66. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $96.28. The company has a market cap of $6.27 billion, a PE ratio of 23.19 and a beta of -0.08. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LNTH. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Truist Financial restated a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a report on Thursday, May 7th. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $99.71.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.